Colchicine induced rhabdomyolysis.
A 59-year-old man with chronic obstructive pulmonary disease (COPD), atrial fibrillation, and gout developed acute dyspnea, cough, and diffuse muscle aches and pains. He had commenced colchicine (0.6 mg b.i.d. p.o.), for the first time, one month earlier for recurrent gout attacks. Clinical examination revealed atrial fibrillation, an exacerbation of his pulmonary disease, tender muscles, especially calves, and diffuse muscle weakness. Laboratory results included creatinine phosphokinase 6961 U/l (1% MB), microscopic hematuria, myoglobinuria, elevated creatinine 1.6 mg/dl, and blood urea nitrogen 17 mg/dl. COPD and atrial fibrillation were treated and colchicine was discontinued. The patient made a full recovery. This 2nd reported case of colchicine induced rhabdomyolysis is the first reported in the treatment of gout.
Dawson
T M
TM
Department of Medicine, VA Puget Sound Health Care System, Seattle 98108, USA.
Starkebaum
G
G
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D003078:Colchicine / Q000009:adverse effects* / Q000627:therapeutic use; D006073:Gout / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000188:drug therapy
D000305:Adrenal Cortex Hormones; D003078:Colchicine